海上钢琴师

CVS removing decongestant from shelves after FDA panel says it's ineffective_我的网站

A |     CVS Health is planning to remove one type of a common decongestant from shelves after an advisory committee to the U.S. Food and Drug Administration said it was ineffective earlier this year.The products contain the oral formulation of phenylephrine (PE), which is found in several over-the-counter (OTC) medications.Although PE has been used as a decongestant for nearly a century, experts have been questioning its efficacy for years.The FDA Nonprescription Drugs Advisory Committee unanimously voted in September that PE did not improve nasal congestion any more than a placebo at the dosage given for OTC use.In response, CVS said it is removing products, in which PE is the only active ingredient from store shelves. This means products like Dayquil, which used a combination of active ingredients, will remain available for purchase."We are aware of the FDA Advisory Committee's position on oral phenylephrine (PE) and will follow direction from the FDA to ensure products we sell comply with all laws and regulations," CVS Health said in a statement. "We are removing certain oral cough and cold products that contain phenylephrine as the only active ingredient from CVS Pharmacy stores. Other oral cough and cold products will continue to be offered to meet consumer needs."CVS did not give specifies on brands that will be removed.The FDA told ABC News it has not yet determined whether it no longer considers PE to be a safe and effective medication and has not ordered the product to be removed from shelves. CVS's move is voluntary."The FDA has no further information to provide at this time regarding the timing of any decision the agency may make following the advisory committee meeting," the federal health agency said.The Consumer Healthcare Products Association told ABC News that the advisory committee's recommendation is a non-binding decision and not a change in regulation."FDA is currently in the process of reviewing the regulatory status of oral phenylephrine (PE) following September's advisory committee meeting," CHPA said in a statement. "Until FDA makes a determination on the committee's recommendation, oral PE remains a Category 1 OTC ingredient, which is generally recognized as safe and effective."Concerns were first raised about PE in 2007. Since then, evidence has accumulated showing that the drug offers little to no relief for nasal congestion.Experts believe this is because the body processes the drug before it reaches the nasal passages where it needs to work.It's unclear if other major retail pharmacy chains will follow in CVS's footsteps.Walgreens Boots Alliance would not disclose whether it was planning to remove products with PE from store shelves and said it would defer to the FDA."Walgreens follows FDA regulations. We are closely monitoring the situation and actively partnering with the Walgreens Office of Clinical Integrity and suppliers on appropriate next steps," a Walgreens spokesperson told ABC News.Other major pharmacy chains including Albertsons, Costco and Kroger did immediately reply to ABC News' request for comment. Walmart did not have an answer immediately available.ABC News' Sasha Pezenik and Sony Salzman contributed to this report.。     8 月 25 日消息，Gartner（高德纳）在其当地时间 24 日的新闻稿中预测，2026 年存储器市场规模将达 8,373 亿美元（注：现汇率约合 5.64 万亿元人民币），超过半导体产业整体在 2025 年实现的 8,090 亿美元收入（现汇率约合 5.45 万亿元人民币）。图源：Pexels8,373 亿美元的数据意味着存储器市场规模在短短一年间膨胀了 280.4%，其中 DRAM 增长 246.6%、NAND 增长 371.9%。存储器在半导体产业营收中的占比也将从一年前的 27% 翻倍至 54%，而“存＞非存”的局面至少要延续到 2027 年。

B |
2025 年2026 年2027 年存储器产值2,2018,37310,755非存储器产值5,8907,1798,644总体产值8,09015,55219,399上述金额单位均为亿美元机构预测，全球半导体行业收入今年将达 1.5552 万亿美元（现汇率约合 10.48 万亿元人民币），同比增长 92%；2027 年还将进一步增长 24.7%，逼近 2 万亿美元关口。

C | 人工智能数据中心生态系统在整体产业收入中的占比将从 2026 年的 36.5% 提升至 2030 年的 53% 以上。参考广告声明：文内含有的对外跳转链接（包括不限于超链接、二维码、口令等形式），用于传递更多信息，节省甄选时间，结果仅供参考，包含外链的文章均包含本声明。

Current article:http://2m3so7.shangyaohujunwei.bond/list_vp2/68au.html

Published on:06:49:10